People diagnosed with cancer are more than two-and-a-half times more likely to declare bankruptcy than those without cancer, according to a new study from Fred Hutchinson Cancer Research Center. Researchers also found that younger cancer patients had two- to five-fold higher bankruptcy rates compared to older patients, and that overall bankruptcy filings increased as time passed following diagnosis.
[More]
Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.
[More]
In the latest effort to educate and enable the allergic patient to take control of their disease, ALK, a leading company focusing on allergy treatment, and the Asthma and Allergy Foundation of America have partnered to create a unique online resource for patients.
[More]
The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.
[More]
Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes.
[More]
Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration.
[More]
Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of Cytovir ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.
[More]
An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal congestion and itchy eyes experienced by ragweed allergy sufferers.
[More]
Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center.
[More]
Many of today's school teachers opt for dustless chalk to keep hands and classrooms clean. But according to a study published in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), this choice in chalk may cause allergy and asthma symptoms in students that have a milk allergy.
[More]
Can the patterns in tree branches or the meandering bends in a river provide clues that could lead to better cancer therapies? According to a new study from Virginia Commonwealth University Massey Cancer Center, these self-similar, repeating patterns in nature known as fractals help scientists better understand how the immune system is organized and may one day be used to help improve stem cell transplant outcomes in leukemia patients by predicting the probability of transplant complications.
[More]
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.
[More]
A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.
[More]
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.
[More]
Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.
[More]
Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.
[More]
Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro's vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants.
[More]
Patients from ethnic minority and mixed-racial backgrounds are less likely to receive a lifesaving bone marrow transplant than Caucasian patients with the same disease due to lack of matching donors, according to the National Marrow Donor Program.
[More]
Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the 10th anniversary of his continued cancer-free survival.
[More]
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.
[More]